Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients

One of the biggest challenges in multiple sclerosis (MS) is the definition of treatment response/failure in order to optimize treatment decisions in affected patients. The objective of this consensus was to review how disease activity should be assessed and to propose recommendations on the identification of treatment failure in RRMS patients in Argentina. A panel of experts in neurology from Argentina, dedicated to the diagnosis and care of MS patients, gathered both virtually and in person during 2016 and 2017 to carry out a consensus recommendation on the identification of treatment failure in RRMS patients. To achieve consensus, the methodology of “formal consensus-RAND/UCLA method” was used. Recommendations were established based on published evidence and the expert opinion. Recommendations focused on disease management, disease activity markers and treatment failure identification were determined. Main consensus were: ≥2 relapses during the first year of treatment and/or ≥3 new or enlarged T2 or T1 GAD+ lesions and/or sustained increase of ≥2 points in EDSS or ≥100% in T25FW defines treatment failure in RRMS patients. The recommendations of this consensus guidelines attempts to optimize the health care and management of patients with MS in Argentina. •The objective of this consensus was to treatment failure in RRMS patients in Argentina.•43 experts from all Argentina defined the treatment failure by formal consensus.•≥2 relapses during the first year of treatment defines treatment failure.•≥3 new or enlarged T2 or T1 GAD+ lesions, defines treatment failure.•Sustained increase of ≥2 points in EDSS or ≥100% in T25FW defines treatment failure.